title: [Current therapeutic options for giant cell arteritis].
abstract: Giant cell arteritis is the most common systemic vasculitis and affects large and medium-sized vessels. Glucocorticoids are the current standard in the therapy of giant cell arteritis. To reduce the glucocorticoid dose the European League Against Rheumatism (EULAR) suggests the addition of disease-modifying antirheumatic drugs. Of these, methotrexate represents the best investigated drug; possible alternatives include azathioprine, tumor necrosis factor-alpha inhibitors and cyclophosphamide.
authors.affiliation: Abteilung für Innere Medizin, A. ö. KH der Elisabethinen, Völkermarkter Str. 15-19, 9020 Klagenfurt am Wörthersee, Osterreich. edith.wipfler@gmx.net
authors.forename: E
authors.initials: E
authors.lastname: Wipfler-Freissmuth
authors.forename: J
authors.initials: J
authors.lastname: Loock
authors.forename: F
authors.initials: F
authors.lastname: Moosig
authors.forename: C
authors.initials: C
authors.lastname: Dejaco
authors.forename: C
authors.initials: C
authors.lastname: Duftner
authors.forename: M
authors.initials: M
authors.lastname: Schirmer
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D013700:Giant Cell Arteritis / Q000188:drug therapy*; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D012219:Rheumatology / Q000639:trends*
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D005938:Glucocorticoids